Cochrane Abstracts
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Direct Factor Xa Inhibitors Versus Low Molecular Weight Heparins or Vitamin K Antagonists for Prevention of Venous Thromboembolism in Elective Primary Hip or Knee Replacement or Hip Fracture Repair." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/440721/all/Direct_factor_Xa_inhibitors_versus_low_molecular_weight_heparins_or_vitamin_K_antagonists_for_prevention_of_venous_thromboembolism_in_elective_primary_hip_or_knee_replacement_or_hip_fracture_repair.
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440721/all/Direct_factor_Xa_inhibitors_versus_low_molecular_weight_heparins_or_vitamin_K_antagonists_for_prevention_of_venous_thromboembolism_in_elective_primary_hip_or_knee_replacement_or_hip_fracture_repair. Accessed April 26, 2025.
Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440721/all/Direct_factor_Xa_inhibitors_versus_low_molecular_weight_heparins_or_vitamin_K_antagonists_for_prevention_of_venous_thromboembolism_in_elective_primary_hip_or_knee_replacement_or_hip_fracture_repair
Direct Factor Xa Inhibitors Versus Low Molecular Weight Heparins or Vitamin K Antagonists for Prevention of Venous Thromboembolism in Elective Primary Hip or Knee Replacement or Hip Fracture Repair [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 April 26]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/440721/all/Direct_factor_Xa_inhibitors_versus_low_molecular_weight_heparins_or_vitamin_K_antagonists_for_prevention_of_venous_thromboembolism_in_elective_primary_hip_or_knee_replacement_or_hip_fracture_repair.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
ID - 440721
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/440721/all/Direct_factor_Xa_inhibitors_versus_low_molecular_weight_heparins_or_vitamin_K_antagonists_for_prevention_of_venous_thromboembolism_in_elective_primary_hip_or_knee_replacement_or_hip_fracture_repair
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
